Lista de obras -

(-)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer

scholarly article by Liang Xu et al published 1 February 2005 in Molecular Cancer Therapeutics

A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients?

artículo científico publicado en 2008

A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer

artículo científico publicado en 2011

A transcriptional fingerprint of estrogen in human breast cancer predicts patient survival

artículo científico publicado en 2008

Activating ESR1 mutations in hormone-resistant metastatic breast cancer

artículo científico publicado en 2013

Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors

artículo científico publicado en 2006

Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine

artículo científico publicado en 2003

An expression signature of estrogen-regulated genes predicts disease-free survival in tamoxifen-treated patients better than progesterone receptor status.

artículo científico publicado en 2008

Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort

artículo científico publicado en 2009

Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy

artículo científico publicado en 2015

Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover

artículo científico publicado en 2015

Attempted replication of SNPs in RANKL and OPG with musculoskeletal adverse events during aromatase inhibitor treatment for breast cancer

artículo científico publicado en 2017

CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial

artículo científico publicado en 2015

CYP2D6 Genotype Should Not Be Used for Deciding About Tamoxifen Therapy in Postmenopausal Breast Cancer ⬇️

artículo científico publicado el 17 de junio de 2013

CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients

artículo científico publicado en 2012

CYP2D6 genotype and tamoxifen response

artículo científico publicado en 2005

CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial

artículo científico publicado en 2012

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment

artículo científico publicado en 2005

CYP2D6 testing for breast cancer patients: is there more to the story?

artículo científico publicado en 2009

Combination vinorelbine and capecitabine for metastatic breast cancer using a non-body surface area dosing scheme

artículo científico publicado en 2005

Comparative analysis of circulating tumor DNA stability In K3EDTA, Streck, and CellSave blood collection tubes.

artículo científico publicado en 2016

Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients

artículo científico publicado en 2010

Comprehensive mutation and copy number profiling in archived circulating breast cancer tumor cells documents heterogeneous resistance mechanisms.

artículo científico publicado en 2017

Concordance Between CYP2D6 Genotypes Obtained From Tumor-Derived and Germline DNA ⬇️

artículo científico publicado el 19 de agosto de 2013

Consensus statement: Expedition Inspiration 2004 Breast Cancer Symposium ?Breast Cancer ? the Development and Validation of New Therapeutics?

article

Correction to: Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer

artículo científico publicado en 2020

Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity

artículo científico publicado en 2016

Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance

scientific article published on September 2008

DNA derived from archival tumor specimens can be used for germline pharmacogenetic analyses

artículo científico publicado en 2020

Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer.

artículo científico publicado en 2014

EGFR and EGFRvIII expression in primary breast cancer and cell lines.

artículo científico publicado en 2004

ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients

artículo científico publicado en 2015

ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer

artículo científico publicado en 2015

ESR1 and PGR polymorphisms are associated with estrogen and progesterone receptor expression in breast tumors

artículo científico publicado en 2016

Effects of SLCO1B1 polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozole

scientific article published on 01 June 2019

Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer

artículo científico publicado en 2016

Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells

artículo científico

Evaluation of novel epidermal growth factor receptor tyrosine kinase inhibitors

artículo científico publicado en 2004

Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines

artículo científico publicado en 2016

Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion

artículo científico publicado en 2019

Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines

artículo científico publicado en 2007

Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226.

artículo científico publicado en 2016

Functional Characterization of a Genetic Polymorphism in the Promoter of the ESR2 Gene ⬇️

artículo científico publicado el 1 de abril de 2012

GREB 1 is a critical regulator of hormone dependent breast cancer growth

artículo científico publicado en 2005

GREB1 is a novel androgen-regulated gene required for prostate cancer growth.

artículo científico publicado en 2006

Genes regulated by estrogen in breast tumor cells in vitro are similarly regulated in vivo in tumor xenografts and human breast tumors

artículo científico publicado en 2006

Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer

artículo científico publicado en 2013

Genetic variation in Charcot-Marie-Tooth genes contributes to sensitivity to paclitaxel-induced peripheral neuropathy

scientific article published on 23 July 2020

Genetic variation in EPHA contributes to sensitivity to paclitaxel-induced peripheral neuropathy

scientific article published on 10 December 2019

Genotyping concordance in DNA extracted from formalin-fixed paraffin embedded (FFPE) breast tumor and whole blood for pharmacogenetic analyses

artículo científico publicado en 2015

Genotyping for polymorphic drug metabolizing enzymes from paraffin-embedded and immunohistochemically stained tumor samples

artículo científico

Germline Genetic Variants in GATA3 and Breast Cancer Treatment Outcomes in SWOG S8897 Trial and the Pathways Study

artículo científico publicado en 2019

Germline genetic predictors of aromatase inhibitor concentrations, estrogen suppression and drug efficacy and toxicity in breast cancer patients.

artículo científico publicado en 2017

Heterogeneous estrogen receptor expression in circulating tumor cells suggests diverse mechanisms of fulvestrant resistance

artículo científico publicado en 2016

Impact of CYP3A5 phenotype on tacrolimus concentrations after sublingual and oral administration in lung transplant

articulo cientifico

Individualized Tamoxifen Dose Escalation-Response

artículo científico publicado en 2016

Individualized Tamoxifen Dose Escalation: Confirmation of Feasibility, Question of Utility

artículo científico publicado en 2016

Infiltrating S100A8+ myeloid cells promote metastatic spread of human breast cancer and predict poor clinical outcome

artículo científico publicado en 2014

Institutional profile of pharmacogenetics within University of Michigan College of Pharmacy

artículo científico publicado en 2017

MDA-MB-435 cells are derived from M14 melanoma cells--a loss for breast cancer, but a boon for melanoma research

artículo científico publicado en 2006

Mechanisms of estrogen-independent breast cancer growth driven by low estrogen concentrations are unique versus complete estrogen deprivation ⬇️

artículo científico publicado el 29 de marzo de 2012

Monitoring serial changes in circulating human breast cancer cells in murine xenograft models

scientific article published on July 2008

One step at a time: CYP2D6 guided tamoxifen treatment awaits convincing evidence of clinical validity

artículo científico publicado en 2016

Osteonecrosis of the Jaw Risk Factors in Bisphosphonate Treated Patients with Metastatic Cancer

artículo científico publicado en 2020

Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer

artículo científico publicado en 2016

Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response?

artículo científico publicado en 2008

Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes

artículo científico publicado en 2005

Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing?

artículo científico publicado en 2009

Pharmacogenomics and Endocrine Therapy in Breast Cancer

artículo científico publicado en 2019

Re: Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies

artículo científico publicado en 2015

Response

artículo científico publicado en 2014

Sequence diversity and functional characterization of the 5'-regulatory region of human CYP2C19.

artículo científico publicado en 2003

Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer

artículo científico publicado en 2020

The CYP17A1 inhibitor abiraterone exhibits estrogen receptor agonist activity in breast cancer

artículo científico publicado en 2016

The Metabolism, Analysis, and Targeting of Steroid Hormones in Breast and Prostate Cancer

artículo científico publicado en 2016

The androgen metabolite 5alpha-androstane-3beta,17beta-diol (3betaAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance

artículo científico publicado en 2008

The endocannabinoid anandamide is a substrate for the human polymorphic cytochrome P450 2D6.

artículo científico publicado en 2008

The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen

artículo científico publicado en 2006

The role of single nucleotide polymorphisms in breast cancer metastasis

artículo científico publicado en 2008

Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism

artículo científico publicado en 2002

Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients

article published in 2017

What does an orphan G-protein-coupled receptor have to do with estrogen?

artículo científico publicado en 2005

When will tumor gene expression profiling be incorporated into clinical breast cancer decision making?

artículo científico publicado en 2006

Whole Genome Amplification of DNA for Genotyping Pharmacogenetics Candidate Genes ⬇️

artículo científico publicado el 30 de marzo de 2012

Lista de obras de

(-)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer

A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients?

A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer

A transcriptional fingerprint of estrogen in human breast cancer predicts patient survival

Activating ESR1 mutations in hormone-resistant metastatic breast cancer

Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors

Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine

An expression signature of estrogen-regulated genes predicts disease-free survival in tamoxifen-treated patients better than progesterone receptor status.

Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort

Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy

Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover

Attempted replication of SNPs in RANKL and OPG with musculoskeletal adverse events during aromatase inhibitor treatment for breast cancer

CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial

CYP2D6 Genotype Should Not Be Used for Deciding About Tamoxifen Therapy in Postmenopausal Breast Cancer ⬇️

CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients

CYP2D6 genotype and tamoxifen response

CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment

CYP2D6 testing for breast cancer patients: is there more to the story?

Combination vinorelbine and capecitabine for metastatic breast cancer using a non-body surface area dosing scheme

Comparative analysis of circulating tumor DNA stability In K3EDTA, Streck, and CellSave blood collection tubes.

Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients

Comprehensive mutation and copy number profiling in archived circulating breast cancer tumor cells documents heterogeneous resistance mechanisms.

Concordance Between CYP2D6 Genotypes Obtained From Tumor-Derived and Germline DNA ⬇️

Consensus statement: Expedition Inspiration 2004 Breast Cancer Symposium ?Breast Cancer ? the Development and Validation of New Therapeutics?

Correction to: Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer

Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity

Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance

DNA derived from archival tumor specimens can be used for germline pharmacogenetic analyses

Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer.

EGFR and EGFRvIII expression in primary breast cancer and cell lines.

ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients

ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer

ESR1 and PGR polymorphisms are associated with estrogen and progesterone receptor expression in breast tumors

Effects of SLCO1B1 polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozole

Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer

Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells

Evaluation of novel epidermal growth factor receptor tyrosine kinase inhibitors

Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines

Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion

Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines

Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226.

Functional Characterization of a Genetic Polymorphism in the Promoter of the ESR2 Gene ⬇️

GREB 1 is a critical regulator of hormone dependent breast cancer growth

GREB1 is a novel androgen-regulated gene required for prostate cancer growth.

Genes regulated by estrogen in breast tumor cells in vitro are similarly regulated in vivo in tumor xenografts and human breast tumors

Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer

Genetic variation in Charcot-Marie-Tooth genes contributes to sensitivity to paclitaxel-induced peripheral neuropathy

Genetic variation in EPHA contributes to sensitivity to paclitaxel-induced peripheral neuropathy

Genotyping concordance in DNA extracted from formalin-fixed paraffin embedded (FFPE) breast tumor and whole blood for pharmacogenetic analyses

Genotyping for polymorphic drug metabolizing enzymes from paraffin-embedded and immunohistochemically stained tumor samples

Germline Genetic Variants in GATA3 and Breast Cancer Treatment Outcomes in SWOG S8897 Trial and the Pathways Study

Germline genetic predictors of aromatase inhibitor concentrations, estrogen suppression and drug efficacy and toxicity in breast cancer patients.

Heterogeneous estrogen receptor expression in circulating tumor cells suggests diverse mechanisms of fulvestrant resistance

Impact of CYP3A5 phenotype on tacrolimus concentrations after sublingual and oral administration in lung transplant

Individualized Tamoxifen Dose Escalation-Response

Individualized Tamoxifen Dose Escalation: Confirmation of Feasibility, Question of Utility

Infiltrating S100A8+ myeloid cells promote metastatic spread of human breast cancer and predict poor clinical outcome

Institutional profile of pharmacogenetics within University of Michigan College of Pharmacy

MDA-MB-435 cells are derived from M14 melanoma cells--a loss for breast cancer, but a boon for melanoma research

Mechanisms of estrogen-independent breast cancer growth driven by low estrogen concentrations are unique versus complete estrogen deprivation ⬇️

Monitoring serial changes in circulating human breast cancer cells in murine xenograft models

One step at a time: CYP2D6 guided tamoxifen treatment awaits convincing evidence of clinical validity

Osteonecrosis of the Jaw Risk Factors in Bisphosphonate Treated Patients with Metastatic Cancer

Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer

Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response?

Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes

Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing?

Pharmacogenomics and Endocrine Therapy in Breast Cancer

Re: Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies

Response

Sequence diversity and functional characterization of the 5'-regulatory region of human CYP2C19.

Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer

The CYP17A1 inhibitor abiraterone exhibits estrogen receptor agonist activity in breast cancer

The Metabolism, Analysis, and Targeting of Steroid Hormones in Breast and Prostate Cancer

The androgen metabolite 5alpha-androstane-3beta,17beta-diol (3betaAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance

The endocannabinoid anandamide is a substrate for the human polymorphic cytochrome P450 2D6.

The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen

The role of single nucleotide polymorphisms in breast cancer metastasis